Literature DB >> 32447045

Pretransplantation Cognitive Dysfunction in Advanced-Age Hematologic Cancers: Predictors and Associated Outcomes.

James C Root1, Claudine Campbell2, Xiomara Rocha-Cadman3, Nicole Kasven-Gonzalez2, Molly Maloy4, Jessica Flynn5, Sean M Devlin5, Ann A Jakubowski6.   

Abstract

Patients presenting for treatment of hematologic cancers may be at increased risk for cognitive dysfunction before allogeneic hematopoietic stem cell transplantation (HSCT) due to advanced age, previous chemotherapy treatment, deconditioning, and fatigue. Cognitive dysfunction may affect treatment decision making, ability to recall or follow post-HSCT treatment recommendations and overall survival (OS). A total of 448 patients admitted for HSCT between 2011 and 2014 were administered the Montreal Cognitive Assessment (MoCA) by occupational therapists during admission before transplantation, and 260 were reassessed following transplantation and before discharge. We examined select predictor variables, including age, Karnofsky Performance Status, sex, disease type, psychotropic medications, and select outcome variables, including OS, and nonrelapse mortality (NRM). Before transplantation, 36.4% of patients met criteria for cognitive dysfunction. Age was found to be a significant predictor, along with disease type (myelodysplastic syndrome [MDS], myeloproliferative disorder [MPD]). No significant association was found between cognitive dysfunction and OS or NRM. Longitudinal analysis from pretransplantation to post-transplantation indicated significant decline following HSCT. Notably, one-third of the study cohort showed cognitive dysfunction at hospital discharge. A significant proportion of HSCT candidates present with cognitive dysfunction, with older patients and those diagnosed with MDS and MPD at greatest risk in this cohort. Attention to cognitive dysfunction before transplantation may alert the treatment team to high-risk cases that require increased oversight, inclusion by caregivers, and referral to occupational therapy at discharge. Longitudinal follow-up studies are needed to clarify the specific effect of HSCT on cognitive dysfunction and the impact of cognitive dysfunction on transplantation outcomes.
Copyright © 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32447045      PMCID: PMC7441498          DOI: 10.1016/j.bbmt.2020.05.010

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  30 in total

1.  Quality of life one year following bone marrow transplantation: psychometric evaluation of the quality of life in bone marrow transplant survivors tool.

Authors:  U S Saleh; D Y Brockopp
Journal:  Oncol Nurs Forum       Date:  2001-10       Impact factor: 2.172

2.  The Role of Age in Neurocognitive Functioning among Adult Allogeneic Hematopoietic Cell Transplant Recipients.

Authors:  Aasha I Hoogland; Ashley M Nelson; Brent J Small; Kelly A Hyland; Brian D Gonzalez; Margaret Booth-Jones; Claudio Anasetti; Paul B Jacobsen; Heather S L Jim
Journal:  Biol Blood Marrow Transplant       Date:  2017-08-07       Impact factor: 5.742

3.  Impact of perceived cognitive impairment in breast cancer survivors.

Authors:  Diane Von Ah; Barbara Habermann; Janet S Carpenter; Brandy L Schneider
Journal:  Eur J Oncol Nurs       Date:  2012-08-14       Impact factor: 2.398

4.  Prospective assessment of white matter integrity in adult stem cell transplant recipients.

Authors:  D D Correa; Y Wang; J D West; K K Peck; J C Root; R E Baser; H T Thaler; T B Shore; A Jakubowski; A J Saykin; N Relkin
Journal:  Brain Imaging Behav       Date:  2016-06       Impact factor: 3.978

5.  Cognitive functioning and quality of life in long-term adult survivors of bone marrow transplantation.

Authors:  Helena Harder; Jan J Cornelissen; Arthur R Van Gool; Hugo J Duivenvoorden; Wil M H Eijkenboom; Martin J van den Bent
Journal:  Cancer       Date:  2002-07-01       Impact factor: 6.860

Review 6.  Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy.

Authors:  Jörg Dietrich; Michelle Monje; Jeffrey Wefel; Christina Meyers
Journal:  Oncologist       Date:  2008-11-19

7.  Changes in cognitive functioning in the year after hematopoietic stem cell transplantation.

Authors:  Sheri R Jacobs; Brent J Small; Margaret Booth-Jones; Paul B Jacobsen; Karen K Fields
Journal:  Cancer       Date:  2007-10-01       Impact factor: 6.860

8.  Chemobrain experienced by breast cancer survivors: a meta-ethnography study investigating research and care implications.

Authors:  Maryam Hafsah Selamat; Siew Yim Loh; Lynette Mackenzie; Janette Vardy
Journal:  PLoS One       Date:  2014-09-26       Impact factor: 3.240

Review 9.  A systematic review and meta-analysis of changes in cognitive functioning in adults undergoing hematopoietic cell transplantation.

Authors:  K M Phillips; H L McGinty; J Cessna; Y Asvat; B Gonzalez; M G Cases; B J Small; P B Jacobsen; J Pidala; H S L Jim
Journal:  Bone Marrow Transplant       Date:  2013-05-06       Impact factor: 5.483

Review 10.  Pretreatment Cancer-Related Cognitive Impairment-Mechanisms and Outlook.

Authors:  Brennan Olson; Daniel L. Marks
Journal:  Cancers (Basel)       Date:  2019-05-16       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.